ANGPTL3-lowering strategies to address residual cardiovascular risk
1. 系统已在2026-04-23 17:24:16对应助文件进行删除
2. 如有需要请重新发布求助信息
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI:
文献链接:
其他信息:
F Mohamed, FJ Raal
Nature Reviews Cardiology, 2026
nature.com
Angiopoietin-related protein 3 (ANGPTL3)-lowering therapies are an LDL receptor-independent strategy for patients who remain at high cardiovascular risk despite conventional treatment, including those with familial hypercholesterolaemia. By reducing both LDL-cholesterol and triglyceride-rich lipoprotein levels in plasma, ANGPTL3 inhibition addresses a broader atherogenic burden and might offer advantages over apolipoprotein C3 inhibition, with the potential to reshape the management of refractory dyslipidaemias …
